Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3

D. P. Modest, T. Denecke, J. Pratschke, I. Ricard, H. Lang, M. Bemelmans, T. Becker, M. Rentsch, D. Seehofer, C. J. Bruns, B. Gebauer, H. I. Modest, S. Held, G. Folprecht, V. Heinemann, U. P. Neumann

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)77-86
Number of pages10
JournalEuropean Journal of Cancer
Volume88
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Metastatic colorectal cancer
  • Resection
  • Conversion therapy
  • Cetuximab
  • Bevacizumab
  • Surgery
  • EXPERT CONSENSUS STATEMENT
  • LIVER METASTASES
  • PHASE-3 TRIAL
  • OPEN-LABEL
  • RESECTION
  • SURVIVAL
  • SURGERY
  • HEPATECTOMY
  • THERAPIES
  • DISEASE

Cite this